ZA201402392B - Compounds and methods for enhancing innate immune responses - Google Patents

Compounds and methods for enhancing innate immune responses

Info

Publication number
ZA201402392B
ZA201402392B ZA2014/02392A ZA201402392A ZA201402392B ZA 201402392 B ZA201402392 B ZA 201402392B ZA 2014/02392 A ZA2014/02392 A ZA 2014/02392A ZA 201402392 A ZA201402392 A ZA 201402392A ZA 201402392 B ZA201402392 B ZA 201402392B
Authority
ZA
South Africa
Prior art keywords
compounds
methods
immune responses
innate immune
enhancing innate
Prior art date
Application number
ZA2014/02392A
Other languages
English (en)
Inventor
Jean-Philippe Therrien
John Bradford Shotwell
Jesse Daniel Keicher
Robert Hamatake
Hamilton D Dickson
John George Catalano
Jonos Botyanszki
Shihyun You
Matthew David Tallant
Christopher Brooks Moore
Hans Hofland
Margaret J Gartland
Wendy Huang Chern
Eric Gregory Burroughs
Anna Lindsey Banka
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of ZA201402392B publication Critical patent/ZA201402392B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2014/02392A 2011-10-21 2014-03-31 Compounds and methods for enhancing innate immune responses ZA201402392B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US201261692431P 2012-08-23 2012-08-23
PCT/US2012/060971 WO2013059559A2 (en) 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses

Publications (1)

Publication Number Publication Date
ZA201402392B true ZA201402392B (en) 2017-09-27

Family

ID=48141628

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/02392A ZA201402392B (en) 2011-10-21 2014-03-31 Compounds and methods for enhancing innate immune responses

Country Status (23)

Country Link
US (1) US20140249143A1 (enExample)
EP (1) EP2768506A4 (enExample)
JP (1) JP2014532626A (enExample)
KR (1) KR20140094559A (enExample)
CN (1) CN103957910A (enExample)
AR (1) AR088793A1 (enExample)
AU (1) AU2012325971B2 (enExample)
BR (1) BR112014008727A2 (enExample)
CA (1) CA2851801A1 (enExample)
CL (1) CL2014001016A1 (enExample)
CO (1) CO6910198A2 (enExample)
CR (1) CR20140175A (enExample)
DO (1) DOP2014000081A (enExample)
EA (1) EA201490610A1 (enExample)
IL (1) IL231894A0 (enExample)
MX (1) MX2014004814A (enExample)
PE (1) PE20141359A1 (enExample)
PH (1) PH12014500865A1 (enExample)
SG (2) SG11201400988SA (enExample)
TW (2) TW201542567A (enExample)
UY (1) UY34406A (enExample)
WO (1) WO2013059559A2 (enExample)
ZA (1) ZA201402392B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
JP2017531631A (ja) 2014-09-29 2017-10-26 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 伝染性軟属腫ウイルスに対する抗ウイルス薬
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗b型肝炎ウイルス剤
EP3601286A4 (en) 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
CA3114551A1 (en) 2018-10-23 2020-04-30 Basf Se Tricyclic pesticidal compounds
CN114732822B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
WO2021209265A1 (en) 2020-04-14 2021-10-21 Basf Se Tricyclic pesticidal compounds
WO2022049521A1 (en) * 2020-09-03 2022-03-10 Glaxosmithkline Intellectual Property Development Limited Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンkras阻害剤
MX2024004444A (es) 2021-10-14 2024-05-08 Incyte Corp Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
AU2024252826A1 (en) * 2023-04-14 2025-10-16 HUMANWELL PHARMACEUTICAL US, Inc. Monoacylglycerol lipase (magl) inhibitors for the treatment of pain and related medical disorders
WO2025089372A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人理化学研究所 イソインドリン誘導体
WO2025128898A1 (en) 2023-12-13 2025-06-19 Assembly Biosciences, Inc. Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59104A (en) * 1979-02-09 1984-02-29 Roussel Uclaf Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ.ホフマン−ラ ロシュ アーゲー イミダゾ縮合化合物
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JP5481671B2 (ja) * 2009-03-31 2014-04-23 ダイキン工業株式会社 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Also Published As

Publication number Publication date
WO2013059559A3 (en) 2013-11-14
CL2014001016A1 (es) 2015-01-16
UY34406A (es) 2013-05-31
SG11201400988SA (en) 2014-07-30
PE20141359A1 (es) 2014-10-13
BR112014008727A2 (pt) 2017-04-25
CN103957910A (zh) 2014-07-30
AR088793A1 (es) 2014-07-10
WO2013059559A2 (en) 2013-04-25
CA2851801A1 (en) 2013-04-25
KR20140094559A (ko) 2014-07-30
EP2768506A2 (en) 2014-08-27
CO6910198A2 (es) 2014-03-31
TW201333003A (zh) 2013-08-16
DOP2014000081A (es) 2014-07-15
SG10201505664WA (en) 2015-09-29
TW201542567A (zh) 2015-11-16
IL231894A0 (en) 2014-05-28
MX2014004814A (es) 2014-05-27
PH12014500865A1 (en) 2014-05-26
AU2012325971B2 (en) 2016-03-31
EP2768506A4 (en) 2015-08-19
JP2014532626A (ja) 2014-12-08
AU2012325971A1 (en) 2014-04-17
US20140249143A1 (en) 2014-09-04
CR20140175A (es) 2014-06-03
EA201490610A1 (ru) 2014-09-30

Similar Documents

Publication Publication Date Title
IL231894A0 (en) Compounds and methods for enhancing innate immune responses
ZA201307919B (en) Composition and method for enhancing an immune response
EP2736330A4 (en) COMPOUNDS AND METHODS
EP2747560A4 (en) CONNECTIONS AND METHODS
PL2696754T3 (pl) Urządzenie i sposób pomiaru stresu
EP2615533A4 (en) INTERACTION PROCEDURE AND INTERACTION DEVICE
EP2788507A4 (en) METHOD FOR MEASURING IMMUNE ACTIVATION
EP2736332A4 (en) CONNECTIONS AND METHODS
IL232213B (en) Antibody Formulations and Methods
EP2736329A4 (en) COMPOUNDS AND METHODS
GB201110783D0 (en) Methods and uses
GB201122089D0 (en) Telecomunication apparatus and methods
EP2755363A4 (en) METHOD AND DEVICE FOR FAST DATA DISTRIBUTION
GB201116774D0 (en) Uses and methods
EP2753062A4 (en) IMAGING DEVICE AND IMAGING METHOD
GB201101862D0 (en) Method and device
SG11201408326TA (en) Preparation method for perfluoro-2-methyl-3-pentanone and intermediate
EP2741748A4 (en) BETA-LACTAM COMPOUNDS FOR IMPROVING T-CELL-MEDIATED IMMUNE REACTIONS
GB201105569D0 (en) Apparatus and methods
EP2717985A4 (en) DEVICE AND METHOD FOR DISTILLATION
GB201113806D0 (en) Food processing
GB201108490D0 (en) Methods and uses
ZA201400185B (en) Food suspension device
HK1195257A (en) Compounds and methods for enhancing innate immune responses
EP2756880A4 (en) DEVICE FOR TREATING POWDERS AND METHOD THEREOF